CD2 and neoplasm: Further challenge with Nalm6-L cells on days seven and twelve resulted in rapid tumor expansion in the CD19-BBζ CAR-T-cell treatment group, while CD19-BBζ + CD2 CAR-T cells continued to effectively restrict tumor growth and prominently improved survival rates (Fig. 5B, C).